Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Tretinoin Liposome in Patients With Recurrent or Refractory Hodgkin's Disease (Summary Last Modified 11/2001)

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Closed	12 and over	NCI	MDA-ID-99255 NCI-103, NCT00005969, 103

Trial Description

Purpose:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Phase II trial to study the effectiveness of liposomal tretinoin in treating patients who have recurrent or refractory Hodgkin's disease.

Eligibility:

• At least 12 years old
• At lest two previous treatment regimens
• Measurable disease
• No previous donor peripheral stem cell or bone marrow transplantation
• No previous retinoids
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive an infusion of liposomal tretinoin every other day for 4 weeks. Treatment may continue for up to six courses. Some patients may undergo stem cell or bone marrow transplant after receiving at least two courses of tretinoin. Patients will be evaluated every 3 months.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

M. D. Anderson Cancer Center at University of Texas

Andreas Sarris, MD, PhD, Protocol chair		Ph: 713-792-2860; 800-392-1611

Registry Information
Official Title		Phase II Study of ATRAGEN (Liposomal Tretinoin) in Patients with Relapsed or Refractory Hodgkin's Disease
Registered in ClinicalTrials.gov		NCT00005969
Date Submitted to PDQ		2000-05-04
Information Last Verified		2001-11-01
NCI Grant/Contract Number		P30-CA16672

Back to Top